Difference between revisions of "Dalpiciclib (SHR-6390)"
Jump to navigation
Jump to search
m |
|||
| Line 15: | Line 15: | ||
[[Category:CDK4 inhibitors]] | [[Category:CDK4 inhibitors]] | ||
[[Category:CDK6 inhibitors]] | [[Category:CDK6 inhibitors]] | ||
| + | |||
| + | [[Category:Breast cancer medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 00:23, 30 April 2022
Mechanism of action
From NCI Drug Dictionary: A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation.
Preliminary data
Breast cancer, ER-positive
- DAWNA-1: NCT03927456
Also known as
- Code name: SHR6390